Human tumor necrosis factor TR21 and methods based thereon
US7112410B1 · kind B1 · utility
6Cited by
0References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 28, 2002 |
| Grant date | Sep 26, 2006 |
| Priority date | — |
| Expiry date | May 8, 2023 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/101
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention relates to TR21 polypeptides. In particular, isolated nucleic acid molecules are provided encoding human TR21 protein. TR21 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR21 activity. The invention further relates to the treatment, diagnosis, or prognosis of autoimmune diseases or disorders including Sjogren's syndrome using TR21 polynucleotides, polypeptides, agonists or antagonists.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.